Reading Time: 3 minutesIntroduction Cognitive decline, particularly in the context of mild cognitive impairment (MCI), represents a significant public health challenge, especially among American males. As the population ages, the prevalence of MCI is expected to rise, underscoring the urgent need for effective therapeutic interventions. Ipamorelin, a selective growth hormone secretagogue, has emerged as a promising candidate in this regard. This article delves into a comprehensive five-year neurological study examining the influence of Ipamorelin on cognitive decline in American males with MCI, shedding light on its potential as a therapeutic agent. Study Design and Methodology The study was conducted over a five-year period, … Continue reading →